Pneumococcal surface protein a-hybrid nanoparticles protect mice from lethal challenge after mucosal immunization targeting the lungs

Full metadata record
DC FieldValueLanguage
dc.contributorLab. de Desenvolvimento de Vacinaspt_BR
dc.contributorLab. Bacteriologiapt_BR
dc.contributor.authorFigueiredo, Douglas Borges dept_BR
dc.contributor.authorKaneko, Kanpt_BR
dc.contributor.authorRodrigues, Tasson da Costapt_BR
dc.contributor.authorMacLoughlin, Ronanpt_BR
dc.contributor.authorMiyaji, Eliane Namiept_BR
dc.contributor.authorSaleem, Imranpt_BR
dc.contributor.authorGonçalves, Viviane Maimonipt_BR
dc.date.accessioned2022-06-20T19:43:19Z-
dc.date.available2022-06-20T19:43:19Z-
dc.date.issued2022pt_BR
dc.identifier.citationFigueiredo DB, Kaneko K, Rodrigues TC, MacLoughlin R, Miyaji EN, Saleem I, et al. Pneumococcal surface protein a-hybrid nanoparticles protect mice from lethal challenge after mucosal immunization targeting the lungs. Pharmaceutics. 2022 June;14(6):1238. doi:10.3390/pharmaceutics14061238.pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/4393-
dc.description.abstractPneumococcal disease remains a global burden, with current conjugated vaccines offering protection against the common serotype strains. However, there are over 100 serotype strains, and serotype replacement is now being observed, which reduces the effectiveness of the current vaccines. Pneumococcal surface protein A (PspA) has been investigated as a candidate for new serotype-independent pneumococcal vaccines, but requires adjuvants and/or delivery systems to improve protection. Polymeric nanoparticles (NPs) are biocompatible and, besides the antigen, can incorporate mucoadhesive and adjuvant substances such as chitosans, which improve antigen presentation at mucosal surfaces. This work aimed to define the optimal NP formulation to deliver PspA into the lungs and protect mice against lethal challenge. We prepared poly(glycerol-adipate-co-ω-pentadecalactone) (PGA-co-PDL) and poly(lactic-co-glycolic acid) (PLGA) NPs using an emulsion/solvent evaporation method, incorporating chitosan hydrochloride (HCl-CS) or carboxymethyl chitosan (CM-CS) as hybrid NPs with encapsulated or adsorbed PspA. We investigated the physicochemical properties of NPs, together with the PspA integrity and biological activity. Furthermore, their ability to activate dendritic cells in vitro was evaluated, followed by mucosal immunization targeting mouse lungs. PGA-co-PDL/HCl-CS (291 nm) or CM-CS (281 nm) NPs produced smaller sizes compared to PLGA/HCl-CS (310 nm) or CM-CS (299 nm) NPs. Moreover, NPs formulated with HCl-CS possessed a positive charge (PGA-co-PDL +17 mV, PLGA + 13 mV) compared to those formulated with CM-CS (PGA-co-PDL −20 mV, PLGA −40 mV). PspA released from NPs formulated with HCl-CS preserved the integrity and biological activity, but CM-CS affected PspA binding to lactoferrin and antibody recognition. PspA adsorbed in PGA-co-PDL/HCl-CS NPs stimulated CD80+ and CD86+ cells, but this was lower compared to when PspA was encapsulated in PLGA/HCl-CS NPs, which also stimulated CD40+ and MHC II (I-A/I-E)+ cells. Despite no differences in IgG being observed between immunized animals, PGA-co-PDL/HCl-CS/adsorbed-PspA protected 83% of mice after lethal pneumococcal challenge, while 100% of mice immunized with PLGA/HCl-CS/encapsulated-PspA were protected. Therefore, this formulation is a promising vaccine strategy, which has beneficial properties for mucosal immunization and could potentially provide serotype-independent protection.pt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.description.sponsorship(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorship(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.description.sponsorship(MRC) Medical Research Councilpt_BR
dc.format.extent1238pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofPharmaceuticspt_BR
dc.rightsOpen accesspt_BR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/pt_BR
dc.titlePneumococcal surface protein a-hybrid nanoparticles protect mice from lethal challenge after mucosal immunization targeting the lungspt_BR
dc.typeArticlept_BR
dc.rights.licenseCC BYpt_BR
dc.identifier.doi10.3390/pharmaceutics14061238pt_BR
dc.identifier.urlhttps://doi.org/10.3390/pharmaceutics14061238pt_BR
dc.contributor.external(USP) Universidade de São Paulopt_BR
dc.contributor.external(LJMU) Liverpool John Moores Universitypt_BR
dc.contributor.externalAerogenpt_BR
dc.identifier.citationvolume14pt_BR
dc.identifier.citationissue6pt_BR
dc.subject.keywordhybrid nanoparticlespt_BR
dc.subject.keywordantigen delivery systempt_BR
dc.subject.keywordStreptococcus pneumoniaept_BR
dc.subject.keywordvaccinept_BR
dc.subject.keywordchitosanpt_BR
dc.subject.keywordPLGApt_BR
dc.subject.keywordmucosal immunizationpt_BR
dc.relation.ispartofabbreviatedPharmaceuticspt_BR
dc.identifier.citationabntv. 14, n. 6, 1238, jun. 2022pt_BR
dc.identifier.citationvancouver2022 June;14(6):1238pt_BR
dc.contributor.butantanFigueiredo, Douglas Borges de|:Desvinculado|:Lab. de Desenvolvimento de Vacinas|:PrimeiroAutorpt_BR
dc.contributor.butantanRodrigues, Tasson da Costa|:Desvinculado|:Lab. Bacteriologiapt_BR
dc.contributor.butantanGonçalves, Viviane Maimoni|:Pesquisador|:Lab. de Desenvolvimento de Vacinas|:Autor de correspondênciapt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2017/26090-7pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2016/50413-8pt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦140573/2015-1pt_BR
dc.sponsorship.butantan(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior¦¦pt_BR
dc.sponsorship.butantan(MRC) Medical Research Council¦¦MR/P022758/1pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.fulltextCom Texto completo-
item.openairetypeArticle-
item.grantfulltextopen-
item.languageiso639-1English-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0002-0980-8116-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos de periódicos


Files in This Item:

pharmaceutics-14-01238-v2.pdf
Description:
Size: 3.07 MB
Format: Adobe PDF
View/Open
Show simple item record

This item is licensed under a Creative Commons License Creative Commons